Our Research and Development Focus

CSL's research and development program focuses on protein-based medicines purified from human plasma, made from traditional sources as with influenza vaccines or produced using recombinant DNA technology.

Our scientists work on new product development, life-cycle management and product safety. We also have strong relationships with academic and corporate research partners.

Plasma Products
Developments in our plasma products portfolio include chromatographic liquid intravenous immunoglobulins, improved coagulation products for haemophilia and new treatments for von Willebrand disease.

Iscomatrix® Adjuvant
CSL's Iscomatrix® adjuvant is now produced at our Kankakee site in the US as well as in Australia as we continue to make good progress with commercialising this proprietary technology.

Influenza Vaccine
International demand for our influenza vaccines is strong and we recently filed a Biologics License Application for the registration of our vaccine in the US. We also recently applied to Australia's Therapeutic Goods Administration for registration of a prototype pandemic influenza vaccine that we have developed.

Recombinant Antibody Technology
Our investment in recombinant monoclonal antibody technology (rMAB) includes a number of pre-clinical candidates and three of these will enter clinical trials in the next year.

Back | Next